More than 1,500 pages of internal VA records, obtained through a Freedom of Information Act request filed by the Veterans Action Council, offer the most detailed public view yet into how the Department of Veterans Affairs has been implementing its cannabis policy-and what federal rescheduling could actually mean for veterans who rely on VA healthcare. The documents confirm meaningful institutional progress. They also expose real gaps that policy language alone cannot fix.
What the FOIA Records Actually Show
The records center on VHA Directive 1315, the foundational policy document governing how VA clinicians engage with veteran cannabis users. Across the released materials-cover letters, internal communications, provider education packets-the directive is cited between six and ten times. That level of repetition is not incidental. It reflects deliberate institutional reinforcement, an effort to make the policy operational rather than decorative.
The core message running through those materials is consistent: providers are required to discuss cannabis use with patients. They must document it. And critically, they cannot deny care to a veteran solely because that veteran participates in a state-approved medical cannabis program. That protection has been in place, in some form, since 2010-built largely through sustained advocacy by veterans including Michael Krawitz, whose early-2000s organizing helped move VA from outright hostility toward formal engagement.
The contrast with earlier practice is not subtle. VAC member Etienne Fontan was removed from four VA facilities by security in the 1990s simply for mentioning his cannabis use. The idea that acknowledging the subject constituted grounds for exclusion from care was, at the time, operationally real. The shift from that posture to a written requirement that providers engage in clinical discussion represents a genuine change in institutional culture-one worth stating plainly before cataloguing what remains broken.
Rescheduling's Specific Impact on VA Clinical Authority
Here's where the rescheduling question gets specific. Under cannabis's longtime Schedule I classification, VA clinicians have been explicitly prohibited from recommending cannabis or certifying veterans for state medical programs. One document in the FOIA release acknowledges directly that moving cannabis to Schedule III "might affect a VA provider's ability to refer VA patients to State medical cannabis treatment programs." That language is careful-deliberately so-but the implication is clear. Rescheduling would remove a legal barrier that has prevented VA doctors from doing something that state-licensed physicians in legal markets can already do.
That said, the documents are equally clear that rescheduling is not a wholesale policy reset. Any expansion of provider authority-referrals to state programs, formal recommendations-would require separate legal and policy review before becoming operational at VA. The standard of care for mental health conditions, in particular, will not shift automatically. The Office of Mental Health and Suicide Prevention guidance obtained via FOIA is explicit: the core framework of Directive 1315 remains intact under Schedule III. Providers will still document. Discussions will still be required. The architecture of the policy does not dissolve; specific restrictions within it may be revised through a separate process.
For licensed cannabis operators-particularly those running medical dispensaries in states with significant veteran populations-this matters. A pathway for VA providers to formally refer patients to state programs, even if still months or years away from operational reality, would represent a structural change in how some veterans access the medical market. It would not be a consumer marketing opportunity. It would be a compliance and access question: which programs are eligible, what documentation would be required, and how VA's coordination-of-care obligations interact with state licensing frameworks.
Where the Policy Falls Short in Practice
The FOIA records show a system trying to get the policy right at the communication level. They also reveal where that effort stops well short of what veterans actually experience.
The clearest gap is veteran awareness. VA published a public-facing video about Directive 1315 roughly twelve years after the policy's foundation was established. Many veterans still do not know the directive exists-which means they walk into clinical appointments afraid to disclose cannabis use, expecting a punitive response that would, under current policy, be both prohibited and unethical. The policy protects them. They just don't know it.
A second structural problem runs in the opposite direction: clinicians are being bombarded with anti-drug and drug-misuse-focused communications that, in practice, can obscure or effectively contradict the intent of the cannabis directive. A provider absorbing a steady stream of substance-misuse warnings may reasonably default to a cautious or dismissive posture toward cannabis discussions-even while technically obligated to have them.
The VAC analysis also found no evidence of continuing medical education cannabis courses being distributed systemwide, and no documented actions at individual facility level to train staff on the cannabis directive. That absence explains something veterans have reported anecdotally for years: the experience of trying to discuss cannabis with a VA provider varies wildly from clinic to clinic, sometimes from one appointment to the next within the same facility. Uniform policy has not produced uniform practice.
What This Means for the Regulated Cannabis Industry
For cannabis operators and compliance professionals, the takeaway is not that the VA is about to become a referral pipeline. It isn't-not yet, and possibly not soon. What the FOIA release does confirm is that the policy infrastructure supporting veteran access to medical cannabis is being actively maintained and will not be abandoned as rescheduling moves forward. That is its own kind of market signal.
Veterans represent a medically distinct patient population with documented rates of chronic pain, PTSD, and other conditions that drive medical cannabis use in regulated markets. If rescheduling eventually enables VA providers to formally refer patients to state programs, operators in those states-particularly those already serving medical patients under strict compliance regimes-will need to understand what that referral pathway looks like, what documentation it produces, and how it interacts with existing patient intake and verification requirements.
None of that is imminent. But the direction is clear, and the policy architecture supporting it is real. For an industry that routinely plans around regulatory timelines measured in years, that is precisely the kind of signal worth tracking now.
